Semaglutide and tirzepatide are both FDA-approved for weight loss and both highly effective. Tirzepatide produces more weight loss on average. Semaglutide has stronger cardiovascular evidence. The right choice depends on your clinical situation.
By Dr. Teja V. Surapaneni, MD, MS • Board-Certified Internal Medicine • May 2026
Semaglutide (Wegovy) and tirzepatide (Zepbound) are both FDA-approved for weight management and both highly effective. Tirzepatide produces more weight loss on average. Semaglutide has a longer track record and stronger cardiovascular evidence. The right choice depends on your clinical situation, comorbidities, and goals.
| Factor | Semaglutide (Wegovy) | Tirzepatide (Zepbound) |
|---|---|---|
| Mechanism | GLP-1 agonist | GLP-1 + GIP dual agonist |
| Average weight loss (max dose) | ~14.9% (STEP 1) | ~22.5% (SURMOUNT-1) |
| Patients losing ≥20% | 18% | 36% |
| Injection frequency | Once weekly | Once weekly |
| Maximum dose | 2.4mg weekly | 15mg weekly |
| CV indication (non-diabetic obesity) | Yes (SELECT trial) | Pending (SURPASS-CVOT) |
| Sleep apnea indication | No | Yes (SURMOUNT-OSA) |
| Brand list price | ~$1,349/month | ~$1,059/month |
The SELECT trial (2023) demonstrated a 20% reduction in major cardiovascular events (heart attack, stroke, cardiovascular death) in patients with established cardiovascular disease and obesity/overweight — without diabetes. This is the only GLP-1 with completed cardiovascular outcomes data for non-diabetic obesity. If you have had a heart attack, stroke, or have peripheral arterial disease, semaglutide has a specific FDA indication and strong trial data for cardiovascular risk reduction. Tirzepatide’s cardiovascular outcomes trial is ongoing.
Following SELECT, Medicare Part D covers Wegovy for cardiovascular risk reduction in eligible patients. Zepbound does not have this indication yet. For Medicare patients with cardiovascular disease, semaglutide may be the only covered option.
On average, tirzepatide produces 6–8% more weight loss than semaglutide. For patients with significant obesity (BMI 35+) or obesity-related comorbidities where more weight loss translates directly to better outcomes (knee arthritis, sleep apnea, heart failure, mobility limitations), the superior efficacy of tirzepatide is clinically meaningful.
Tirzepatide is the first FDA-approved drug treatment for moderate-to-severe obstructive sleep apnea — approved in 2024 based on SURMOUNT-OSA. Up to 50% of patients no longer met OSA criteria after one year on tirzepatide. For patients with obesity + OSA, tirzepatide has a specific indication that semaglutide does not.
Patients who have been on maximally-dosed semaglutide for 6+ months and plateaued frequently resume weight loss after switching to tirzepatide. The dual GIP mechanism adds an effect that GLP-1 alone does not provide, making the switch an evidence-based escalation strategy.
For patients with established cardiovascular disease: semaglutide’s SELECT data is compelling and provides Medicare coverage. For patients whose primary goal is maximum weight loss or who have OSA: tirzepatide’s superior efficacy and specific indications make it the stronger argument. Both are available as compounded versions at YourMD — semaglutide from $199/month, tirzepatide from $399/month — for patients who cannot access branded versions.
This article is for informational purposes only and does not constitute medical advice. Always consult with a licensed physician before starting any medication.
No credit card required. Live MD consult included.